Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...
The long-acting insulin, which will treat millions of diabetes patients, is the result of a 2022 partnership between Egyptian firm Eva Pharma and global pharmaceutical giant Eli Lilly and Company.
Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants over the price of insulin.
The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). Launched in 2022, the collaboration aims to deliver a ...
Under this agreement, Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to ...
The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company. Launched in 2022, the collaboration aims to deliver a ...
EVA Pharma ( ) through a collaboration with Eli Lilly and Company (NYSE ... regulatory approval of EVA Pharma's insulin drug products, following Lilly and EVA Pharma's collaboration ...